NCT02265913View on ClinicalTrials.gov

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

PHASE3CompletedINTERVENTIONAL
Enrollment

4,076

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

April 27, 2016

Study Completion Date

November 21, 2017

Conditions
Herpes Labialis
Interventions
DRUG

Acyclovir 5 percent (Perrigo)

DRUG

Acyclovir 5 percent (Reference)

DRUG

Placebo cream

Trial Locations (1)

68114

Quality Clinical Research Inc, Omaha

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT02265913 - Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis | Biotech Hunter | Biotech Hunter